Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70140 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, 2025. Written by Yasuhiro Takagi and 14 co-authors. Institution: Department of Gastroenterology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan. Major MEDLINE topics: Colitis, Ulcerative, Antibodies, Monoclonal, Humanized. Cited 29 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real‐world evidence for mirikizumab.
Aim
To evaluate the real‐world effectiveness and safety of mirikizumab.
Methods
In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy.
Results
We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3–6] to 2 [0–3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9–7.3] to 1.8 [0.5–4.0] mg/L, p = 0.015; LRG: 20.1 [16.3–23.2] to 15.9 [12.8–23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death.
Conclusion
This real‐world study demonstrated the short‐term effectiveness and safety of mirikizumab in patients with UC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
- Center for Inflammatory Bowel Disease, Division of Gastroenterology, Department of Internal Medicine, Tokyo Yamate Medical Center, Tokyo, Japan.
- Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
- Department of Biostatistics, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
ORCID profiles: Yasuhiro Takagi, Toshiyuki Sato, Akira Nogami, Masataka Igeta, Maiko Ikenouchi, Masayuki Fukata, Taku Kobayashi, Shinichiro Shinzaki
Cite
APA
Takagi, Y., Sato, T., Nishiguchi, T., Nogami, A., Igeta, M., Yagi, S., Ikenouchi, M., Kawai, M., Kamikozuru, K., Yokoyama, Y., Tomita, T., Fukui, H., Fukata, M., Kobayashi, T., & Shinzaki, S. (2025). Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70140
Vancouver
Takagi Y, Sato T, Nishiguchi T, Nogami A, Igeta M, Yagi S, et al. Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70140
BibTeX
@article{Takagi2025,
author = {Takagi, Yasuhiro and Sato, Toshiyuki and Nishiguchi, Takanori and Nogami, Akira and Igeta, Masataka and Yagi, Soichi and Ikenouchi, Maiko and Kawai, Mikio and Kamikozuru, Koji and Yokoyama, Yoko and Tomita, Toshihiko and Fukui, Hirokazu and Fukata, Masayuki and Kobayashi, Taku and Shinzaki, Shinichiro},
title = {Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70140}
}
EUVIMED